Cmv and tb vaccine study in healthy adults
Part of Infections clinical trials.
This trial tests an experimental vaccine called VIR-1778 that may help protect against infections caused by two viruses: cytomegalovirus (CMV) and tuberculosis (TB). The study looks at whether the vaccine is safe and how well it works in healthy adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are generally healthy and have no significant medical conditions.
- You have had cytomegalovirus (CMV) in the past.
- You have not had tuberculosis (TB) or been in close contact with someone with active TB in the last 2 years.
- You are willing to use condoms during the study, even if you cannot get pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
This study measures how strongly your immune system responds to COVID-19 vaccines. It includes people with newly diagnosed tuberculosis and a healthier comparison group, aiming to understand vaccine immune effects and safety.
This early-phase trial tests a new vaccine designed to prevent tuberculosis (TB). It helps researchers see if the vaccine is safe and produces an immune response in healthy adults. Participation may contribute to the development of a new prevention tool for TB.
This Phase 3 study tests whether MTBVAC can safely protect newborn babies from tuberculosis and whether it helps the baby’s immune system learn to fight TB. If you enroll, the goal is to see safety and immune response in real newborn settings in sub-Saharan Africa.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This study tests a daily combination of two medicines, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13 years old. It aims to see if this short treatment is safe and works well for kids, including those living with HIV.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.